Global Dyspepsia Drugs Market Insights Forecasts to 2033

• The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023
• The Market Size is Growing at a CAGR of 4.46% from 2023 to 2033
• The Worldwide Dyspepsia Drugs Market Size is Expected to Reach USD 14.7 Billion by 2033
• North America is Expected to Grow the fastest during the forecast period.

The Global Dyspepsia Drugs Market Size is Anticipated to Exceed USD 14.7 Billion by 2033, Growing at a CAGR of 4.46% from 2023 to 2033.

Market Overview

Dyspepsia is defined as chronic or recurrent pain or discomfort centered in the upper abdomen, mainly in or around the midline as opposed to the right or left hypochondrium. It is a sensation of pain or discomfort in the upper abdomen. It can be characterized as burning, gnawing, early satiety, indigestion, gassiness, or postprandial fullness. Organic dyspepsia has a known cause and might be identified through medical examinations, whereas functional dyspepsia has a discernible organic cause. Treatment of functional dyspepsia generally involves symptom management and lifestyle changes such as adjusting diet, avoiding foods that trigger symptoms, managing stress, and taking symptom relievers such as antacids. On the other hand, in the case of organic dyspepsia, treatment will be aimed at addressing the underlying organic cause, such as antibiotics for H. pylori infection or drugs that reduce stomach acid production. There are various medications and treatments available, depending on the cause of dyspepsia. Medication options include antacids, H-2 receptor antagonists, PPIs (proton pump Inhibitors), prokinetics, antibiotics, and antidepressants. There are a variet of heartburn medicines available over the counter to ease symptoms. Nonprescription medications used to treat heartburn include antacids such as aluminum hydroxide gel, calcium carbonate, magnesium hydroxide, Gaviscon, Gelusil, Maalox, Mylanta, Rolaids, and pepto-bismol, while acid reducers include cimetidine, famotidine, and nizatidine. Combination therapy may lead to bigger improvement in overall efficacy and health-related quality of life in patients with functional dyspepsia than the use of motility medicine alone. Zegerid OTC is the combination of PPI and sodium bicarbonate. These drugs are available for treating dyspepsia. The introduction of novel therapies such as prokinetic agents, mucoprotective agents, and neuromodulators, is presenting new opportunities for market growth.  

Report Coverage

This research report categorizes the market for the global dyspepsia drugs market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global dyspepsia drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global dyspepsia drugs market.

Driving Factors

The prevalence of functional dyspepsia increased significantly with age, reaching 48.3% at ages more than 60 years. Thus, the rising aging population is contributing to propelling the market demand for dyspepsia drugs. Heartburn (88%), gastrointestinal pain (31%), and acid regurgitation (32%) are the commonest reasons for heartburn and most people use dyspepsia drugs thus it is the commonest way of dyspepsia treatment. The increasing preference for OTC medications (antacids and PPIs) and their accessibility in retail pharmacies as retail pharmacies stock a wide range of over-the-counter (OTC) dyspepsia drugs, providing consumers with immediate access to symptom-relief options. Thus, the availability of a wide range of products in retail outlets contributes to the market growth for dyspepsia drugs.

 Restraining Factors

The side effects associated with dyspepsia drugs and the availability of alternative therapies are restraining the global dyspepsia drugs market.

Market Segmentation

The global dyspepsia drugs market share is classified into indication, drug type, medication, mode, and distribution channel.

• The functional dyspepsia segment accounted for the largest revenue share of the global dyspepsia drugs market in 2023.

Based on the indication, the global dyspepsia drugs market is categorized into functional dyspepsia and organic dyspepsia. Among these, the functional dyspepsia segment accounted for the largest revenue share of the global dyspepsia drugs market in 2023. It is non-ulcer dyspepsia that refers to recurring symptoms of an upset stomach with no obvious cause. It is a common type of functional disorder with an estimated 10-20% of people seeking healthcare for their symptoms might have functional dyspepsia. Thus, the rising cases of functional dyspepsia lead to drive the market demand in the functional dyspepsia segment.

• The proton pump inhibitors segment is expected to hold the largest share of the global dyspepsia drugs market during the forecast period.

Based on the drug type, the global dyspepsia drugs market is categorized into proton pump inhibitors, H-2 receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. Among these, the proton pump inhibitors segment is expected to hold the largest share of the global dyspepsia drugs market during the forecast period. Proton pump inhibitors have been established as an effective treatment for functional dyspepsia reducing stomach acid, and prokinetics accelerate stomach emptying. Proton pump inhibitors (PPI) are more effective at relieving overall dyspepsia symptoms.

• The branded segment is anticipated to grow at the fastest CAGR during the forecast period.

Based on the medication, the global dyspepsia drugs market is categorized into branded and generic. Among these, the branded segment is anticipated to grow at the fastest CAGR during the forecast period. Branded drugs have improved drug absorption, reduced side effects, or enhanced overall effectiveness, providing an advantage over generic alternatives. Thus, the growing adoption of branded medicine leads to driving the market in the branded segment.

• The over-the-counter segment dominated the market with the largest revenue share through the forecast period.

Based on the mode, the global dyspepsia drugs market is categorized into over-the-counter and prescription. Among these, the over-the-counter segment dominated the market with the largest revenue share through the forecast period. There are a variety of heartburn medicines available over the counter to ease symptoms. OTC antacids such as Tums or Gaviscon are used to treat mild or occasional indigestion. Various OTC drugs are available for purchase over-the-counter (OTC) from pharmacies to treat dyspepsia.  

• The retail pharmacies segment dominated the market with the largest market share in 2023.

Based on the distribution channel, the global dyspepsia drugs market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Among these, the retail pharmacies segment dominated the market with the largest market share in 2023. Governments in many countries have deregulated the retail pharmacy market to offer easier and broader access to pharmacy services. The retail pharmacy industry has become increasingly competitive over the past decades. 

Regional Segment Analysis of the Global Dyspepsia Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia-Pacific is anticipated to hold the largest share of the global dyspepsia drugs market over the predicted timeframe.

Asia-Pacific is projected to hold the largest share of the global dyspepsia drugs market over the forecast period. The increased prevalence of H.pylori-associated dyspepsia leads to increasing demand for pharmacological therapy for H.pylori influencing market growth for dyspepsia drugs. Further, urbanization and changing lifestyles leading to unhealthy diets and sedentary lifestyles are collectively driving the market in the region.  

North America is expected to grow at the fastest CAGR growth of the global dyspepsia drugs market during the forecast period. The increasing prevalence of GERD (gastroesophageal reflux disease) surging the demand for PPIs and H2 blockers. The growing cases of dyspepsia with the increased investment in healthcare infrastructure are contributing to the market growth in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global dyspepsia drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AstraZeneca plc.
• Pfizer Inc.
• Sanofi
• Abbott Laboratories
• Salix Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Procter & Gamble
• Haleon plc
• ANI Pharmaceuticals, Inc.
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2023, Meiji Seika Pharma and Zeria Pharmaceutical announced that their functional dyspepsia treatment Acofide (acotiamide) has been granted regulatory approval in Thailand.

• In February 2020, Dr. Reddy's Laboratories announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets approved by the U.S. Food and Drug Administration (USFDA).

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global dyspepsia drugs market based on the below-mentioned segments: 

Global Dyspepsia Drugs Market, By Indication

• Functional Dyspepsia
• Organic Dyspepsia

Global Dyspepsia Drugs Market, By Drug Type

• Proton Pump Inhibitors
• H-2 Receptor Antagonists
• Antacids
• Antibiotics
• Prokinetics
• Antidepressants

Global Dyspepsia Drugs Market, By Medication

• Branded
• Generic

Global Dyspepsia Drugs Market, By Mode

• Over-The-Counter
• Prescription

Global Dyspepsia Drugs Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Dyspepsia Drugs Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa